A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03783442 |
Recruitment Status :
Active, not recruiting
First Posted : December 21, 2018
Last Update Posted : May 2, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Esophageal Squamous Cell Carcinoma (ESCC) | Drug: Cisplatin Drug: Oxaliplatin Drug: Fluorouracil (5-FU) Drug: Capecitabine Drug: Paclitaxel Drug: Tislelizumab Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 649 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma |
Actual Study Start Date : | December 11, 2018 |
Estimated Primary Completion Date : | September 30, 2023 |
Estimated Study Completion Date : | September 30, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Tislelizumab + chemotherapy
Tislelizumab administered with chemotherapy doublet: Doublet A: Cisplatin or Oxaliplatin plus Fluorouracil (5-FU); Doublet B: Cisplatin or Oxaliplatin plus Capecitabine; Doublet C: Cisplatin or Oxaliplatin plus Paclitaxel |
Drug: Cisplatin
60 to 80 mg/m^2 intravenously (IV) on Day 1 once every 3 weeks (Q3W) Drug: Oxaliplatin 130 mg/m^2 IV on Day 1 Q3W Drug: Fluorouracil (5-FU) 750 to 800 mg/m^2 IV continuous infusion over 24 hours daily on Days 1 to 5 Q3W Drug: Capecitabine 1000 mg/m^2 orally (PO) twice daily (BID) on Days 1 to 14 Q3W Drug: Paclitaxel 175 mg/m^2 IV on Day 1 Q3W Drug: Tislelizumab 200 mg IV Q3W |
Active Comparator: Placebo + chemotherapy
Placebo administered with chemotherapy doublet: Doublet A: Cisplatin or Oxaliplatin plus Fluorouracil (5-FU); Doublet B: Cisplatin or Oxaliplatin plus Capecitabine; Doublet C: Cisplatin or Oxaliplatin plus Paclitaxel |
Drug: Cisplatin
60 to 80 mg/m^2 intravenously (IV) on Day 1 once every 3 weeks (Q3W) Drug: Oxaliplatin 130 mg/m^2 IV on Day 1 Q3W Drug: Fluorouracil (5-FU) 750 to 800 mg/m^2 IV continuous infusion over 24 hours daily on Days 1 to 5 Q3W Drug: Capecitabine 1000 mg/m^2 orally (PO) twice daily (BID) on Days 1 to 14 Q3W Drug: Paclitaxel 175 mg/m^2 IV on Day 1 Q3W Drug: Placebo Placebo to match Tislelizumab |
- Overall Survival (OS) [ Time Frame: Up to approximately 40 months from date of the first participant randomization ]OS is defined as the time from the date of randomization until the date of death due to any cause
- Progression-Free Survival (PFS) [ Time Frame: Approximately 40 months from date of the first participant randomization ]PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first
- Objective Response Rate (ORR) [ Time Frame: Approximately 40 months from date of the first participant randomization ]ORR is defined as the proportion of participants whose best overall response (BOR) is complete response (CR) or partial response (PR) assessed by the investigator per RECIST v1.1
- Overall survival (OS) in the PD-L1 score ≥ 10% subgroup [ Time Frame: Approximately 40 months from date of the first participant randomization ]OS is defined as the time from the date of randomization until the date of death due to any cause
- Duration of Response (DOR) [ Time Frame: Approximately 40 months from date of the first participant randomization ]DOR is defined as the time from the first determination of an objective response until the first documentation of progression assessed by the investigator per RECIST v1.1 or death, whichever comes first
- Health-Related Quality of Life (HRQoL) assessment of the participant's overall health status using European Quality of Life-Core 30 Questionnaire index (EORTC QLQ-C30) [ Time Frame: Approximately 40 months from date of the first participant randomization ]
- Health-Related Quality of Life (HRQoL) assessment of the participant's overall health status using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire esophageal cancer specific module (EORTC QLQ-OES18) [ Time Frame: Approximately 40 months from date of the first participant randomization ]
- Health-Related Quality of Life (HRQoL) assessment of the participant's overall health status using the generic health state instrument European Quality of Life-5 Dimensions (EuroQol 5D EQ-5D-5L) [ Time Frame: Approximately 40 months from date of the first participant randomization ]
- Number of participants experiencing Adverse Events (AEs) [ Time Frame: Approximately 40 months from date of the first participant randomization ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Participants with unresectable, locally advanced recurrent or metastatic ESCC who have Stage IV unresectable ESCC at first diagnosis (ie, Stage IV disease at the original diagnosis of ESCC) or who have unresectable, locally advanced recurrent or metastatic disease with at least a 6-month treatment-free interval, if prior definitive therapy (chemotherapy, chemo-radiation therapy or surgery) was given.
Key Inclusion Criteria:
- Pathologically (histologically) confirmed diagnosis of ESCC
- Stage IV unresectable ESCC at first diagnosis OR unresectable, locally advanced recurrent or metastatic disease (per American Joint Committee on Cancer 7th Edition), if there is prior neoadjuvant/adjuvant therapy with platinum-based chemotherapy, a treatment-free interval of at least 6 months is required.
Key Exclusion Criteria:
- Palliative radiation treatment for ESCC within 4 weeks of study treatment initiation
- Prior systemic therapy for unresectable, locally advanced recurrent or metastatic ESCC
- Received prior therapies targeting programmed cell death protein-1 (PD-1), programmed cell death protein ligand-1 (PD-L1) or PD-L2
- Participants with evidence of fistula (either esophageal/bronchial or esophageal/aorta)
- Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention (clinically significant recurrence requiring an additional intervention within 2 weeks of intervention)
- Evidence of complete esophageal obstruction not amenable to treatment
- Unintentional weight loss ≥ 5% within one month prior to randomization or Nutritional Risk Index (NRI) < 83.5 per investigator's choice
- Locally advanced esophageal carcinoma that is resectable or potentially curable with radiation therapy per local investigator.
- Participants with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers whose HBV DNA is ≥ 500 IU/mL or participants with active hepatitis C virus (HCV)
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03783442

Study Director: | Liyun Li, MD | BeiGene |
Responsible Party: | BeiGene |
ClinicalTrials.gov Identifier: | NCT03783442 |
Other Study ID Numbers: |
BGB-A317-306 2018-000587-28 ( EudraCT Number ) CTR20181013 ( Other Identifier: Center for drug evaluation, CFDA ) JapicCTI-194741 ( Registry Identifier: Japic ) |
First Posted: | December 21, 2018 Key Record Dates |
Last Update Posted: | May 2, 2022 |
Last Verified: | April 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma Carcinoma, Squamous Cell Esophageal Squamous Cell Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Esophageal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Head and Neck Neoplasms Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases |
Paclitaxel Fluorouracil Capecitabine Oxaliplatin Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antimetabolites Antimetabolites, Antineoplastic Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |